-
Company Insights
Innovation and Patenting activity of LegoChem Biosciences Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of LegoChem Biosciences Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Delpazolid in Mycobacterium Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Delpazolid in Mycobacterium Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Delpazolid in Mycobacterium Infections Drug Details: Delpazolid (LCB-010371) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Delpazolid in Streptococcal Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Delpazolid in Streptococcal Pneumonia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Delpazolid in Streptococcal Pneumonia Drug Details: Delpazolid (LCB-010371) is under development for...
-
Product Insights
NewPulmonary Tuberculosis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Pulmonary Tuberculosis Clinical Trial Report Overview A total of 504 pulmonary tuberculosis clinical trials were conducted as of April 2024. The pulmonary tuberculosis clinical trial report provides a comprehensive understanding of the pulmonary tuberculosis clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·      North America ·      ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LCB-84 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LCB-84 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LCB-84 in Solid Tumor Drug Details: LCB-84 is under development for...
-
Product Insights
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Methicillin-Resistant Staphylococcus Aureus (MRSA) Clinical Trial Report Overview A total of 418 MRSA clinical trials were conducted as of January 2024. The MRSA clinical trial report provides a comprehensive understanding of the MRSA clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe ·       ...
-
Product Insights
Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections - Drugs In Development, 2023’, provides an overview of the Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Methicillin-Susceptible Staphylococcus aureus (MSSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Pulmonary Tuberculosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Pulmonary Tuberculosis - Drugs In Development, 2023’, provides an overview of the Pulmonary Tuberculosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pulmonary Tuberculosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Streptococcal Pneumonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Streptococcal Pneumonia - Drugs In Development, 2023’, provides an overview of the Streptococcal Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Streptococcal Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Middle East Respiratory Syndrome (MERS) – Drugs In Development, 2023
Global Markets Direct’s, ‘Middle East Respiratory Syndrome (MERS) - Drugs In Development, 2023’, provides an overview of the Middle East Respiratory Syndrome (MERS) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...